Back to School Savings: Save up to 30% on print books and eBooks. No promo code needed.

Back to School Savings: Save up to 30%

Clinical Applications of Noncoding RNAs in Cancer

1st Edition - January 19, 2022

Editors: Subash Gupta, Kishore Challagundla

Paperback ISBN:

9 7 8 - 0 - 1 2 - 8 2 4 5 5 0 - 7

eBook ISBN:

9 7 8 - 0 - 1 2 - 8 2 4 5 5 1 - 4

Clinical Applications of Noncoding RNAs in Cancer summarizes the existing strategies, advances, and future opportunities on the role of noncoding RNAs in cancer patients.… Read more

Image - Clinical Applications of Noncoding RNAs in Cancer

Purchase Options

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Clinical Applications of Noncoding RNAs in Cancer summarizes the existing strategies, advances, and future opportunities on the role of noncoding RNAs in cancer patients. Established clinicians and researchers from all around the world share their views and expertise and provide readers with invaluable knowledge on the subject.

This book provides a comprehensive collection of information on the utility of noncoding RNAs in the diagnosis, prognosis, and therapy of cancer. It also discusses the evolutionary significance of noncoding RNAs and how the molecular tools such as RNA-seq, RNA-FISH, ic-SHAPE, and quantitative real-time PCR help in the detection and elucidation of the functions of noncoding RNAs. Additionally, the challenges associated with noncoding RNA approaches and future developments are discussed.

It is a valuable resource for cancer researchers, oncologists, clinicians, and other biomedical field members who want to learn more about noninvasive ways to diagnose and efficiently treat diverse cancer types.

Cover image
Title page
Table of Contents
Copyright
List of contributors
Preface
Chapter 1. Noncoding ribonucleic acid for pancreatic cancer therapy
Abstract
1.1 Introduction
1.2 Experimental methods and tools for analyzing noncoding RNAs in pancreatic cancer patients
1.3 Bioinformatics for analyzing noncoding RNAs in pancreatic cancer patients
1.4 Noncoding RNA
1.5 Pancreatic cancer–specific microRNAs
1.6 Pancreatic cancer–associated lncRNAs
1.7 Pancreatic cancer–associated circular RNAs
1.8 Diagnostic microRNA markers of PDAC
1.9 Diagnostic lncRNA markers of PDAC
1.10 Diagnostic circular RNA markers of PDAC
1.11 Summary and conclusion
Acknowledgment
References
Chapter 2. Applications of noncoding RNAs in brain cancer patients
Abstract
2.1 Introduction
2.2 Data sets for noncoding RNAs analysis
2.3 Expression of noncoding RNAs in brain cancer patients
2.4 Experimental methods and tools for analyzing noncoding RNAs in brain cancer patients
2.5 Noncoding RNAs as predictive marker for brain cancer patients
2.6 Potential of noncoding RNAs in predicting chemoresistance and radioresistance in brain cancer patients
2.7 Therapeutic potential and targeting of ncRNAs in brain cancer patients—challenges and perspectives
2.8 Summary and conclusions
References
Chapter 3. Noncoding RNAs in patients with colorectal cancer
Abstract
3.1 Introduction
3.2 Experimental methods and tools for analyzing noncoding RNAs in colorectal cancer patients
3.3 Microarray
3.4 Serial analysis of gene expression
3.5 Cap analysis gene expression
3.6 RNA sequencing
3.7 Dataset and bioinformatics for analyzing noncoding RNAs in colorectal cancer patients
3.8 Expression of noncoding RNAs in colorectal cancer patients
3.9 Sample types used for analyzing noncoding RNAs
3.10 Cell signaling pathways modulated by noncoding RNAs in colorectal cancer patients
3.11 Several other mechanisms
3.12 Clinical applications of noncoding RNAs as biomarkers in patients with colorectal cancer
3.13 Diagnostic potential of noncoding RNAs in colorectal cancer patients
3.14 Prognostic potential of noncoding RNAs in colorectal cancer patients
3.15 Therapeutic potential of noncoding RNAs in colorectal cancer patients
3.16 Potential of noncoding RNAs in predicting chemoresistance and radioresistance in colorectal cancer patients
3.17 Conclusion
References
Chapter 4. Applications of noncoding ribonucleic acids in multiple myeloma patients
Abstract
4.1 Introduction
4.2 Samples and experimental methods for the analysis of noncoding RNAs in multiple myeloma patients
4.3 Datasets analyzing noncoding RNAs in multiple myeloma patients
4.4 Noncoding RNAs implicated in the etiology of multiple myeloma
4.5 Cell signaling pathways modulated by noncoding RNAs in multiple myeloma
4.6 Noncoding RNAs affecting interactions with the bone marrow niche
4.7 Noncoding RNAs as diagnostic and prognostic biomarkers in multiple myeloma
4.8 Therapeutic potential of noncoding RNAs in multiple myeloma patients
4.9 Summary and conclusion
Acknowledgments
References
Chapter 5. Clinical applications of noncoding RNAs in lung cancer patients
Abstract
Abbreviations
5.1 Introduction
5.2 Experimental methods and tools for analyzing ncRNAs in lung cancer patients
5.3 Datasets and informatics for analyzing ncRNAs in lung cancer patients
5.4 Expression of ncRNAs in lung cancer patients
5.5 Sample types used for analyzing ncRNAs
5.6 Cell signaling pathways modulated by ncRNAs in lung cancer patients
5.7 NcRNAs as predictive markers for lung cancer patients
5.8 Diagnostic potential of ncRNAs in lung cancer patients
5.9 Prognostic potential of ncRNAs in lung cancer patients
5.10 Therapeutic potential of ncRNAs in lung cancer patients
5.11 Potential of ncRNAs in predicting chemoresistance and radioresistance in lung cancer patients
5.12 Summary and conclusion
Acknowledgments
References
Chapter 6. Noncoding RNAs in intraocular tumor patients
Abstract
6.1 Introduction
6.2 Retinoblastoma
6.3 Uveal melanoma
6.4 Conclusion
References
Chapter 7. Applications of noncoding RNAs in renal cancer patients
Abstract
7.1 Introduction
7.2 Datasets and informatics for analyzing noncoding RNAs in renal cancer patients
7.3 Expression of noncoding RNAs in renal cancer patients
7.4 Cell signaling pathways modulated by noncoding RNAs in renal cancer patients
7.5 Diagnostic potential of noncoding RNAs in renal cancer patients
7.6 Prognostic potential of noncoding RNAs in renal cancer patients
7.7 Therapeutic potential of noncoding RNAs in renal cancer patients
7.8 Potential of noncoding RNAs in predicting chemoresistance and radioresistance in renal cancer patients
7.9 Summary and conclusion
References
Chapter 8. Clinical significance of long noncoding RNAs in breast cancer patients
Abstract
Abbreviations
8.1 Introduction
8.2 Potential of lncRNAs in the diagnosis of breast cancer
8.3 Potential of lncRNAs in the prognosis of breast cancer
8.4 Potential of lncRNAs in breast cancer therapy
8.5 Potential of lncRNAs in predicting breast cancer patient’s response to therapeutics
8.6 Potential of lncRNAs in predicting chemoresistance and radioresistance in breast cancer patients
8.7 Experimental methods and tools for analyzing noncoding RNAs in cancer patients
8.8 Summary and conclusion
Acknowledgment
References
Chapter 9. Noncoding ribonucleic acids in gastric cancer patients
Abstract
9.1 Introduction
9.2 Experimental methods and tools for analyzing noncoding RNAs in gastric cancer patients
9.3 Expression of noncoding RNAs in gastric cancer patients
9.4 Sample types used for analyzing noncoding RNAs (tumor biopsies, liquid biopsies, etc.)
9.5 Cell signaling pathways modulated by noncoding RNAs in gastric cancer patients
9.6 Noncoding RNAs as prognostic and predictive marker for gastric cancer patients
9.7 Diagnostic value of small noncoding RNAs in gastric cancer
9.8 Potential of noncoding RNAs in predicting chemotherapy resistance and radiotherapy resistance in gastric cancer patients
9.9 Summary and conclusion
References
Chapter 10. Noncoding RNAs in prostate cancer patients
Abstract
10.1 Introduction
10.2 Experimental methods and tools for analyzing ncRNAs in prostate cancer patients
10.3 Datasets and informatics for analyzing noncoding RNAs
10.4 Sample types used for analyzing ncRNAs (tumor biopsies, liquid biopsies, etc.)
10.5 Cell signaling pathways modulated by ncRNAs in prostate cancer
10.6 NcRNAs as biomarkers for prostate cancer
10.7 Therapeutic potential of ncRNAs in prostate cancer patients
10.8 Potential of ncRNAs in predicting chemo-resistance and radioresistance in prostate cancer patients
10.9 Conclusion
References
Chapter 11. Noncoding RNAs in liver cancer patients
Abstract
Abbreviations
11.1 Introduction
11.2 NcRNA roles in liver development and functions
11.3 Noncoding RNA detection
11.4 Expression of ncRNAs in liver cancers
11.5 Noncoding RNA relevance in liver cancer diagnosis and prognosis
11.6 Summary and conclusion
Acknowledgments
References
Chapter 12. Noncoding ribonucleic acids in gallbladder cancer patients
Abstract
12.1 Introduction
12.2 MiRNAs in gallbladder carcinoma
12.3 LncRNAs in gallbladder carcinoma
12.4 PiRNAs in gallbladder carcinoma
12.5 Limitations of clinical utility of ncRNAs in gallbladder carcinoma
12.6 Conclusion
References
Chapter 13. Clinical implications of noncoding RNAs in neuroblastoma patients
Abstract
13.1 Introduction
13.2 Types of noncoding RNAs
13.3 Role of noncoding RNAs in neuroblastoma growth and development
13.4 Clinical significance of noncoding RNAs in neuroblastoma
13.5 Therapeutic implications and targeting strategies for noncoding RNAs in neuroblastoma
13.6 Conclusion
Acknowledgments
Conflict of interest
References
Chapter 14. Potential clinical application of lncRNAs in pediatric cancer
Abstract
14.1 Introduction
14.2 Experimental and bioinformatics tools for studying lncRNAs
14.3 LncRNAs in pediatric cancer
14.4 Conclusion and perspectives
Acknowledgment
References
Index

Subash Gupta

Dr. Subash Chandra Gupta is an additional professor and Head at the Department of Biochemistry, All India Institute of Medical Sciences, Guwahati, India. He is currently on lien from Banaras Hindu University, Varanasi, India. Dr. Gupta did his postdoctoral training from the Ohio State University and the University of Texas MD Anderson Cancer Center in the United States. Before joining the Banaras Hindu University, Dr. Gupta was an instructor at the University of Mississippi Medical Center in the United States. His current research is focused on uncovering the mechanism by which acidic microenvironment promote cancer growth. He is also working on cancer chemoprevention and on projects to elucidate the role of inflammatory pathways, cancer stem cells, exosomal microRNAs, and long noncoding RNAs in regulating tumor development. He has published over 100 peer-reviewed articles in highly prestigious journals. He has been honored with prestigious national and international awards. He has coedited special issues of scientific journals and three prestigious books. Currently he is an editorial board member on several scientific journals and an active reviewer on more than 80 journals.

Affiliations and expertise

Additional Professor and Head, Department of Biochemistry, All India Institute of Medical Sciences, Guwahati, India

Kishore Challagundla

Dr. Kishore B. Challagundla is an assistant professor in the Department of Biochemistry and Molecular Biology, the Children’s Health Research Institute, and a member of the NCI-designated Fred & Pamela Buffet Cancer Center at the University of Nebraska Medical Center in Omaha, NE, United States. Dr. Challagundla earned a master’s in Biochemistry from Bharathidasan University and a PhD in Biochemistry from the University of Lucknow, followed by postdoctoral training at the Mayo Clinic in Rochester, Minnesota Oregon Health & Science University in Portland, Oregon, and Children's Hospital Los Angeles in California. Challagundla 's lab research focuses on investigating the involvement of novel noncoding RNAs in therapy resistance, the role of exosomes in the cross-talk between tumor, microenvironment, and immune cells, the posttranslational modifications of immune checkpoint molecules by ubiquitination, and their potential role in escaping immune surveillance, the development of RNA-based diagnostic, prognostic, and therapy response predictive specific noninvasive biomarkers in body fluids, and the development of novel combination therapeutic strategies that maximize drug response without any toxicity in patients with high-risk neuroblastoma. Dr. Challagundla served as the principal investigator of several grants, including NIH, foundation, and institutional grants. Dr. Challagundla is an ad hoc reviewer to various national and international organizations such as NIH, Yorkshire Cancer Research (UK), University Grants Committee (Hong Kong), Dutch Cancer Society (The Netherlands), The Netherlands Organisation for Scientific Research (The Netherlands), Worldwide Cancer Research, The Indonesian Science Fund, The National Science Centre (Poland), The French National Cancer Institute (France), The Israel Science Foundation (Israel), Czech Science Foundation (Czech Republic), and The Natural Sciences and Engineering Research Council of Canada. Furthermore, Challagundla is an associate editor of various journals such as Molecular Therapy Nucleic Acids (Cell Press), Molecular Therapy Oncolytics (Cell press), PLoS One, BMC Molecular & Cellular Biology, Cancer Cell International, and an editorial board member of Cancers, The Journal of Extracellular Vesicles, and an active reviewer for more than 100 top international journals. Challagundla has published over 40 peer-reviewed articles in high-impact journals, written several book chapters, and is a recipient of various national and international awards.

Affiliations and expertise

Assistant Professor, Department of Biochemistry and Molecular Biology, Fred and Pamela Buffet Cancer Center, University of Nebraska Medical Center, USA